여포세포 유래 갑상선암의 유전자 이상

키워드

참고문헌 (116)

1. Burman KD, "Unusual types of thyroid neoplasms", Endocrinol Metab Clin North Am, 25, pp.49~68 (1996)
2. Riesco-Eizaguirre G, "New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy", Endocr Relat Cancer, 14, pp.957~77 (2007)
3. Wreesmann V, "Clinical impact of molecular analysis on thyroid cancer management", Surgical Oncology Clinics of North America, 17, pp.1~35 (2008)
4. El-Shabrawi Y, "Anti-tumour necrosis factor alpha treatment in chronic recurrent inflammation of the anterior segment of the eye in patients resistant to standard immunomodulatory treatment", Ann Rheum Dis, 62, pp.1243~1244 (2003)
5. Roque L, "Chromosome imbalances in thyroid follicular neoplasms: a comparison between follicular adenomas and carcinomas", Genes Chromosomes Cancer, 36, pp.292~302 (2003)
6. Kitamura Y, "Allelotyping of follicular thyroid carcinoma: frequent allelic losses in chromosome arms 7q, 11p, and 22q", J Clin Endocrinol Metab, 86, pp.4268~4272 (2001)
7. Castro P, "Adenomas and follicular carcinomas of the thyroid display two major patterns of chromosomal changes", J Pathol, 206, pp.305~311 (2005)
8. Wreesmann VB, "Follicular variant of papillary thyroid carcinoma: genome-wide appraisal of a controversial entity", Genes Chromosomes Cancer, 40, pp.355~364 (2004)
9. Roque L, "Karyotypic characterization of papillary thyroid carcinomas", Cancer, 92, pp.2529~2538 (2001)
10. Singh B, "Screening for genetic aberrations in papillary thyroid cancer by using comparative genomic hybridization", Surgery, 128, pp.888~893 (2000)
11. Kjellman P, "Gain of 1q and loss of 9q21.3-q32 are associated with a less favorable prognosis in papillary thyroid carcinoma", Genes Chromosomes Cancer, 32, pp.43~49 (2001)
12. Roque L, "Cytogenetic and fluorescence in situ hybridization studies in a case of anaplastic thyroid carcinoma", Cancer Genet Cytogenet, 103, pp.7~10 (1998)
13. Mark J, "Cytogenetical observations in five human anaplastic thyroid carcinomas", Hereditas, 107, pp.163~174 (1987)
14. Jenkins RB, "Frequent occurrence of cytogenetic abnormalities in sporadic nonmedullary thyroid carcinoma", Cancer, 66, pp.1213~1220 (1990)
15. Rodrigues RF, "Poorly differentiated and anaplastic thyroid carcinomas: chromosomal and oligo-array profile of five new cell lines", Br J Cancer, 96, pp.1237~1245 (2007)
16. Smallridge RC, "Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies", Endocr Relat Cancer, 16, pp.17~44 (2009)
17. Rapp UR, "Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus", Proc Natl Acad Sci U S A, 80, pp.4218~4222 (1983)
18. Nucera C, "Role of B-Raf (V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf (V600E)", Biochim Biophys Acta, 1795, pp.152~161 (2009)
19. Leicht DT, "Raf kinases: function, regulation and role in human cancer", Biochim Biophys Acta, 1773, pp.1196~212 (2007)
20. Emuss V, "Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF", Cancer Res, 65, pp.9719~9726 (2005)
21. Davies H, "Mutations of the BRAF gene in human cancer", Nature, 417, pp.949~954 (2002)
22. Kumar R, "BRAF mutations in metastatic melanoma: a possible association with clinical outcome", Clin Cancer Res, 9, pp.3362~3368 (2003)
23. Nikiforova MN, "Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells", Science, 290, pp.138~141 (2000)
24. Wan PT, "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF", Cell, 116, pp.855~867 (2004)
25. Nikiforova MN, "BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas", J Clin Endocrinol Metab, 88, pp.5399~5404 (2003)
26. Xing M, "BRAF mutation in thyroid cancer", Endocr Relat Cancer, 12, pp.245~262 (2005)
27. Chung KW, "Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area", Clin Endocrinol (Oxf), 65, pp.660~666 (2006)
28. Jo YS, "Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer", J Clin Endocrinol Metab, 91, pp.3667~3670 (2006)
29. Xing M, "BRAF T1796A transversion mutation in various thyroid neoplasms", J Clin Endocrinol Metab, 89, pp.1365~1368 (2004)
30. Xing M, "BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer", J Clin Endocrinol Metab, 90, pp.6373~6379 (2005)
31. Kim TY, "The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma", Clin Endocrinol (Oxf), 65, pp.364~368 (2006)
32. Riesco-Eizaguirre G, "The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+", I- targeting to the membrane, 2006, pp.13, 257~269
33. Fecher LA, "Toward a molecular classification of melanoma", J Clin Oncol, 25, pp.1606~2620 (2007)
34. Ugolini C, "Presence of BRAF V600E in very early stages of papillary thyroid carcinoma", Thyroid, 17, pp.381~388 (2007)
35. Kim TY, "The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma", Clin Endocrinol (Oxf), 63, pp.588~593 (2005)
36. Mitsutake N, "BRAF mediates RET", PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET, Endocrinology, pp.2006, 147[DOI]
37. Curtin JA, "Distinct sets of genetic alterations in melanoma", N Engl J Med, 353, pp.2135~2147 (2005)
38. Frasca F, "BRAF (V600E) mutation and the biology of papillary thyroid cancer", Endocr Relat Cancer, 15, pp.191~205 (2008)
39. Guan H, "Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer", J Clin Endocrinol Metab, 94, pp.1612~1617 (2009)
40. Suarez HG, "Molecular basis of epithelial thyroid tumorigenesis", C R Acad Sci III, 323, pp.519~528 (2000)
41. Takahashi M, "Activation of a novel human transforming gene, ret, by DNA rearrangement", Cell, 42, pp.581~588 (1985)
42. Fusco A, "A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases", Nature, 328, pp.170~172 (1987)
43. Grieco M, "PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas", Cell, 60, pp.557~563 (1990)
44. Santoro M, "Molecular characterization of RET", PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma, 1994, pp.9, 509~516
45. Miyagi E, "Chronic expression of RET", PTC 3 enhances basal and insulin-stimulated PI3 kinase, Mol Carcinog, pp.2004, 41[DOI]
46. Ouyang B, "Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET", PTC or BRAF mutations in vitro and in vivo, 2006, pp.12, 1785~1793
47. Nikiforov YE, "RET", PTC rearrangement in thyroid tumors, 2002, pp.13, 3~16
48. Nikiforov YE, "Radiation-induced thyroid cancer: what we have learned from chernobyl", Endocr Pathol, 17, pp.307~317 (2006)
49. Thomas GA, "High prevalence of RET", PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET, J Clin Endocrinol Metab, pp.1999, 84[DOI]
50. Ishizaka Y, "Detection of retTPC", PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method, 1991, pp.6, 1667~1672
51. Nikiforova MN, "Prevalence of RET", PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas, 2002, pp.10, 15~22
52. Wirtschafter A, "Expression of the RET", PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis, 1997, pp.107, 95~100
53. Sheils OM, "Ret", PTC-1 Activation in hashimoto thyroiditis, 2000, pp.8, 185~189
54. Elisei R, "RET", PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults, 2001, pp.86, 3211~3216
55. Fenton CL, "The ret", PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults, 2000, pp.85, 1170~1175
56. Adeniran AJ, "Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas", Am J Surg Pathol, 30, pp.216~222 (2006)
57. Zhu Z, "Prevalence of RET", PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity, 2006, pp.91, 3603~3610
58. Chung KW, "RET oncogene expression of papillary thyroid carcinoma in Korea", Surg Today, 34, pp.485~492 (2004)
59. Chung JH, "Detection of RET", PTC oncogene rearrangements in Korean papillary thyroid carcinomas, 1999, pp.9, 1237~1243
60. Knauf JA, "RET", PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase, 2003, pp.22, 4406~4412
61. Harvey JJ, "An unidentified virus which causes the rapid production of tumours in mice", Nature, 204, pp.1104~1105 (1964)
62. Kirsten WH, "Morphologic responses to a murine erythroblastosis virus", J Natl Cancer Inst, 39, pp.311~335 (1967)
63. Garcia-Rostan G, "ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer", J Clin Oncol, 21, pp.3226~3335 (2003)
64. Nikiforov YE, "Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas", Endocr Pathol, 15, pp.319~327 (2004)
65. Lemoine NR, "Activated ras oncogenes in human thyroid cancers", Cancer Res, 48, pp.4459~4463 (1988)
66. Namba H, "Point mutations of ras oncogenes are an early event in thyroid tumorigenesis", Mol Endocrinol, 4, pp.1474~1479 (1990)
67. Vitagliano D, "Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas", Oncogene, 25, pp.5467~5474 (2006)
68. Hihi AK, "PPARs: transcriptional effectors of fatty acids and their derivatives", Cell Mol Life Sci, 59, pp.790~798 (2002)
69. "Science", 2000, 1357~1360
70. Marques AR, "Underexpression of peroxisome proliferator-activated receptor (PPAR)gamma in PAX8", PPARgamma- negative thyroid tumours, 2004, pp.91, 732~738
71. French CA, "Genetic and biological subgroups of low- stage follicular thyroid cancer", Am J Pathol, 162, pp.1053~1060 (2003)
72. Nikiforova MN, "RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma", J Clin Endocrinol Metab, 88, pp.2318~2326 (2003)
73. Kim KY, "Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via proline oxidase-induced reactive oxygen species formation", Mol Pharmacol, 72, pp.674~685 (2007)
74. Govindarajan R, "Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes", J Clin Oncol, 25, pp.1476~1481 (2007)
75. Martelli ML, "Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth", J Clin Endocrinol Metab, 87, pp.4728~4735 (2002)
76. Giordano TJ, "Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation", Clin Cancer Res, 12, pp.1983~1993 (2006)
77. Garcia-Rostan G, "Mutation of the PIK3CA gene in anaplastic thyroid cancer", Cancer Res, 65, pp.10199~10207 (2005)
78. Singh B, "p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas", Genes Dev, 16, pp.984~993 (2002)
79. Robertson GP, "Functional and therapeutic significance of Akt deregulation in malignant melanoma", Cancer Metastasis Rev, 24, pp.273~285 (2005)
80. Kada F, "Akt: a potential target for thyroid cancer therapy", Curr Drug Targets Immune Endocr Metabol Disord, 4, pp.181~185 (2004)
81. Ollikainen M, "Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma", Int J Cancer, 121, pp.915~920 (2007)
82. Davies MA, "A novel AKT3 mutation in melanoma tumours and cell lines", Br J Cancer, 99, pp.1265~1268 (2008)
83. Liu Z, "Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase", akt and mitogen- activated protein kinase pathways in anaplastic and follicular thyroid cancers, 2008, pp.93, 3106~3116
84. Carpten JD, "A transforming mutation in the pleckstrin homology domain of AKT1 in cancer", Nature, 448, pp.439~444 (2007)
85. Liaw D, "Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome", Nat Genet, 16, pp.64~67 (1997)
86. Alvarez-Nunez F, "PTEN promoter methylation in sporadic thyroid carcinomas", Thyroid, 16, pp.17~23 (2006)
87. Hou P, "Genetic alterations and their relationship in the phosphatidylinositol 3-kinase", Akt pathway in thyroid cancer, 2007, pp.13, 1161~1170
88. Halachmi N, "Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors", Genes Chromosomes Cancer, 23, pp.239~243 (1998)
89. Wu G, "Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors", J Clin Endocrinol Metab, 90, pp.4688~4693 (2005)
90. Ringel MD, "Overexpression and overactivation of Akt in thyroid carcinoma", Cancer Res, 61, pp.6105~6111 (2001)
91. Vasko V, "Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer", J Med Genet, 41, pp.161~170 (2004)
92. Yeager N, "Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis", Cancer Res, 67, pp.959~966 (2007)
93. Wang Y, "High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase", akt pathway in thyroid tumors, 2007, pp.92, 2387~2390
94. Hollstein M, "p53 mutations in human cancers", Science, 253, pp.49~53 (1991)
95. Vogelstein B, "p53 function and dysfunction", Cell, 70, pp.523~526 (1992)
96. Freedman DA, "Functions of the MDM2 oncoprotein", Cell Mol Life Sci, 55, pp.96~107 (1999)
97. Jin S, "The p53 functional circuit", J Cell Sci, 114, pp.4139~4140 (2001)
98. Tao W, "P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2", Proc Natl Acad Sci U S A, 96, pp.6937~6941 (1999)
99. Vogelstein B, "Cancer genes and the pathways they control", Nat Med, 10, pp.789~799 (2004)
100. Donghi R, "Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland", J Clin Invest, 91, pp.1753~1760 (1993)
101. Boltze C, "Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma", Int J Oncol, 21, pp.1151~1154 (2002)
102. Saltman B, "Patterns of expression of cell cycle", apoptosis genes along the spectrum of thyroid carcinoma progression, 2006, pp.140, 899~905
103. Onel K, "MDM2 and prognosis", Mol Cancer Res, 2, pp.1~8 (2004)
104. La Perle KM, "Loss of p53 promotes anaplasia and local invasion in ret", PTC1-induced thyroid carcinomas, 2000, pp.157, 671~677
105. Mulholland DJ, "Interaction of nuclear receptors with the Wnt", beta-catenin, Endocr Rev, pp.2005, 26[DOI]
106. Van Aken E, "Defective E-cadherin", catenin complexes in human cancer, 2001, pp.439, 725~751
107. Garcia-Rostan G, "Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis", Am J Pathol, 158, pp.987~996 (2001)
108. Garcia-Rostan G, "Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma", Cancer Res, 59, pp.1811~1815 (1999)
109. Kurihara T, "Immunohistochemical and sequencing analyses of the Wnt signaling components in Japanese anaplastic thyroid cancers", Thyroid, 14, pp.1020~1029 (2004)
110. Mazzanti C, "Using gene expression profiling to differentiate benign versus malignant thyroid tumors", Cancer Res, 64, pp.2898~2903 (2004)
111. Weber F, "Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination", J Clin Endocrinol Metab, 90, pp.2512~2521 (2005)
112. Foukakis T, "A PCR-based expression signature of malignancy in follicular thyroid tumors", Endocr Relat Cancer, 14, pp.381~391 (2007)
113. Fan C, "Concordance among gene-expression-based predictors for breast cancer", N Engl J Med, 355, pp.560~569 (2006)
114. Wang Y, "Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer", Lancet, 365, pp.671~679 (2005)
115. Brown LM, "Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue", Mol Carcinog, 45, pp.613~626 (2006)
116. Netea-Maier RT, "Discovery and validation of protein abundance differences between follicular thyroid neoplasms", Cancer Res, 68, pp.1572~1580 (2008)

관련 논문AI추천